Copertina

Dietary BCAA supplementation counteracts the beneficial effects of long‐term aerobic exercise against obesity and associated metabolic disorders by suppressing FGF21 expression

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jun Zhang, Xuejiao Zhang, Peiyuan Li, Yajin Liu, Chengnan Zhang, Mingyue Lu, Lei Gao, Zhenqiang Song, Haipeng Sun, Junqiang Qiu
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Diabetes, Obesity and Metabolism
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Role of protein arginine methyltransferase 1 in obesity‐related metabolic disorders: Research progress and implications
di: Xiaolei Xuan, et al.
Pubblicazione: (2024)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
di: Iskandar Idris
Pubblicazione: (2024)

Chemerin loss‐of‐function attenuates glucagon‐like peptide‐1 secretion in exercised obese mice
di: Qilong Zhang, et al.
Pubblicazione: (2025)

Association of overweight/obesity and overweight/obesity‐related metabolic dysfunction‐associated steatotic liver disease in young adults with coronary artery calcification later in life
di: Jia‐Jie Wang, et al.
Pubblicazione: (2024)

Involvement of the FTO A > T polymorphism in body composition and lipid profile changes after aerobic training in adults with overweight and obesity
di: Herik Fonseca, et al.
Pubblicazione: (2026)

Sexually Dimorphic Impacts of Early Life BCAAs Supplementation on Metabolic Dysfunctions in Adult Mice
di: Qianqian Yue, et al.
Pubblicazione: (2026)

Post‐semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system
di: Ning Wang, et al.
Pubblicazione: (2026)

Islet‐derived exosomal miR ‐204 accelerates insulin resistance in skeletal muscle by suppressing sirtuin 1: An in vivo study in a mouse model of high‐fat diet–induced obesity
di: Xuehan Yang, et al.
Pubblicazione: (2024)

Aerobic exercise improves energy and glucose homeostasis through hypothalamic Mitofusion 2‐rescued endoplasmic reticulum stress in diet‐induced obese mice
di: Siyan Zhang, et al.
Pubblicazione: (2024)

The effects of anti‐obesity medications on bone metabolism: A critical appraisal
di: Athanasios D. Anastasilakis, et al.
Pubblicazione: (2025)

Impact of bariatric surgery on glycaemic and metabolic outcomes in people with obesity and type 2 diabetes mellitus: A meta‐analysis
di: Xu Han, et al.
Pubblicazione: (2025)

GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
di: Tommaso Bucci, et al.
Pubblicazione: (2025)

Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
di: Jonathan Brix Winther, et al.
Pubblicazione: (2024)

Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity exercise training in adults at risk for metabolic syndrome
di: Steven K. Malin, et al.
Pubblicazione: (2026)

Changes in thyroid hormones predict weight regain in patients with obesity who undergo metabolic surgery
di: Yi Tang, et al.
Pubblicazione: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
di: Iskandar Idris
Pubblicazione: (2024)

Beyond diabetes and obesity: GLP ‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation
di: Renata Spezani, et al.
Pubblicazione: (2025)

Individual and joint associations of obesity and metabolic health parameters on arterial stiffness: Evidence from the UK Biobank
di: Roshan A. Ananda, et al.
Pubblicazione: (2024)

Monlunabant in adults with obesity and metabolic syndrome: Open‐label extension of a phase 2a trial
di: Filip K. Knop, et al.
Pubblicazione: (2026)

Investigating the common genetic architecture and causality of metabolic disorders with neurodegenerative diseases
di: Hao Hong, et al.
Pubblicazione: (2024)

Long‐term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction‐associated fatty liver disease in adults with obesity and type 2 diabetes
di: Michelle D. Lundholm, et al.
Pubblicazione: (2024)

Cannabidiol improves metabolic profiles and alleviates liver inflammation and fibrosis in conditions of androgenic obesity and polycystic ovary syndrome
di: Francisco J. Ponce‐Díaz, et al.
Pubblicazione: (2025)

Plasma leukotriene B 4 decreases after bariatric–metabolic surgery in severe obesity: A prospective observational study
di: Seiji Nishikage, et al.
Pubblicazione: (2025)

The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials
di: Rachelle Haber, et al.
Pubblicazione: (2024)

Real‐world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre‐diabetes
di: Scott A. Coon, et al.
Pubblicazione: (2025)

Novel metabolic and inflammatory stratification of overweight/obesity to characterize risks of adverse outcomes: A large population‐based cohort study
di: Hang Dong, et al.
Pubblicazione: (2025)

Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
di: Shobha Bhattachar, et al.
Pubblicazione: (2026)

Modelling and assessment of glucose‐lactate kinetics in youth with overweight, obesity and metabolic dysfunction‐associated steatotic liver disease: A pilot study
di: Jacopo Bonet, et al.
Pubblicazione: (2024)

The impact of metabolic heterogeneity of obesity and transitions on cardiovascular disease incidence in Chinese middle‐aged and elderly population: A nationwide prospective cohort study
di: Qiang He, et al.
Pubblicazione: (2024)

Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes
di: Zhimin Xu, et al.
Pubblicazione: (2024)

Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study
di: Jheng‐Yan Wu, et al.
Pubblicazione: (2025)

The effects of antihypertensive drugs on glucose metabolism
di: Zhe Li, et al.
Pubblicazione: (2024)

Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study
di: Huilin Tang, et al.
Pubblicazione: (2025)

The role of the glucagon‐FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition
di: Maria Moreno‐Lopez, et al.
Pubblicazione: (2024)

Newly defined clinical obesity versus body mass index ‐defined obesity: Differential risks of overall death and adverse events in a population‐based cohort
di: Li‐You Lian, et al.
Pubblicazione: (2025)

Comment on “Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin–activin–follistatin– IGF ‐1 axis”
di: Caoxu Zhang, et al.
Pubblicazione: (2025)

Efficacy of a low‐carbohydrate diet combined with exercise on glycemic control and metabolic health in type 2 diabetes mellitus: A systematic review and meta‐analysis
di: Ye He, et al.
Pubblicazione: (2025)

Low‐calorie, high‐protein diets, regardless of protein source, improve glucose metabolism and cardiometabolic profiles in subjects with prediabetes or type 2 diabetes and overweight or obesity
di: Carmen Rodrigo‐Carbó, et al.
Pubblicazione: (2024)

Attenuation of brown adipocyte whitening in high‐fat diet‐induced obese rats: Effects of melatonin and β‐hydroxybutyrate on Cidea, Fsp27 and MT1 expression
di: Mohammad Hasan Maleki, et al.
Pubblicazione: (2024)

Associations between obesity indices and cognitive function: Evidence from a middle‐aged observational and Mendelian randomisation study
di: Sisi Luan, et al.
Pubblicazione: (2025)